Context Therapeutics (CNTX) stock price, chart and financials

Price chart

Revenue (trailing twelve months)

—

Revenue (quarter)

—

Revenue growth (year over year)

—

Gross profit (trailing twelve months)

—

Gross margin

—

Net income (trailing twelve months)

—

Net income (quarter)

−$14.6M

Net income growth (year over year)

−64.92%

Net margin

—

Return on equity

−76.14%

EPS (trailing twelve months)

−$0.48

Book value per share

$0.42

P/E (trailing twelve months)

—

Price to book

0.66

Debt to assets

17.26%

Payout ratio

—

Dividend yield

—

Company profile

Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of various therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody (bsAb) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.

• How do I buy stock in Context Therapeutics (CNTX)?

  CNTX trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.